Does the media prefer RVMD or VRTX?

In the previous week, Revolution Medicines had 12 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 72 mentions for Revolution Medicines and 60 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.53 beat Revolution Medicines' score of 0.86 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 36 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Positive Vertex Pharmaceuticals 54 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer RVMD or REGN?

In the previous week, Revolution Medicines had 6 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 72 mentions for Revolution Medicines and 66 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.13 beat Revolution Medicines' score of 0.86 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 36 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Positive Regeneron Pharmaceuticals 46 Very Positive mention(s) 2 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RVMD or ARGX?

In the previous week, Revolution Medicines had 53 more articles in the media than argenex. MarketBeat recorded 72 mentions for Revolution Medicines and 19 mentions for argenex. Revolution Medicines' average media sentiment score of 0.86 beat argenex's score of 0.40 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 36 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Positive argenex 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MRNA or RVMD?

In the previous week, Moderna had 8 more articles in the media than Revolution Medicines. MarketBeat recorded 80 mentions for Moderna and 72 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.86 beat Moderna's score of 0.41 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 35 Very Positive mention(s) 16 Positive mention(s) 7 Neutral mention(s) 10 Negative mention(s) 10 Very Negative mention(s) Neutral Revolution Medicines 36 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Positive

Does the media favor NTRA or RVMD?

In the previous week, Revolution Medicines had 28 more articles in the media than Natera. MarketBeat recorded 72 mentions for Revolution Medicines and 44 mentions for Natera. Natera's average media sentiment score of 1.21 beat Revolution Medicines' score of 0.86 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 32 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Revolution Medicines 36 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Positive

Revolution Medicines (RVMD) Competitors

$207.88 -13.27 (-6.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

RVMD vs. VRTX, REGN, ARGX, MRNA, and NTRA

Should you buy Revolution Medicines stock or one of its competitors? Revolution Medicines's main competitors and comparable companies include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), and Natera (NTRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Revolution Medicines (NASDAQ:RVMD) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Revolution Medicines currently has a consensus target price of $198.89, suggesting a potential downside of 4.32%. Vertex Pharmaceuticals has a consensus target price of $563.50, suggesting a potential upside of 4.03%. Given Vertex Pharmaceuticals' higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.92

Revolution Medicines has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Revolution Medicines' net margin of 0.00%. Vertex Pharmaceuticals' return on equity of 23.09% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

In the previous week, Revolution Medicines had 12 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 72 mentions for Revolution Medicines and 60 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.53 beat Revolution Medicines' score of 0.86 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	36 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	4 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	54 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,847.75	-$1.13B	-$8.82	N/A
Vertex Pharmaceuticals	$12.00B	11.46	$3.95B	$17.18	31.53

Summary

Vertex Pharmaceuticals beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Revolution Medicines (NASDAQ:RVMD) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Revolution Medicines has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

Revolution Medicines currently has a consensus price target of $198.89, suggesting a potential downside of 4.32%. Regeneron Pharmaceuticals has a consensus price target of $800.36, suggesting a potential upside of 0.78%. Given Regeneron Pharmaceuticals' higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.60

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Revolution Medicines had 6 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 72 mentions for Revolution Medicines and 66 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.13 beat Revolution Medicines' score of 0.86 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	36 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	4 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	46 Very Positive mention(s)	2 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Revolution Medicines' net margin of 0.00%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Regeneron Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,847.75	-$1.13B	-$8.82	N/A
Regeneron Pharmaceuticals	$14.34B	5.70	$4.50B	$40.46	19.63

Summary

Regeneron Pharmaceuticals beats Revolution Medicines on 9 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to argenex?

Revolution Medicines (NASDAQ:RVMD) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

argenex has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,847.75	-$1.13B	-$8.82	N/A
argenex	$5.23B	12.25	$1.29B	$26.04	39.29

Revolution Medicines has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, argenex has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Revolution Medicines presently has a consensus target price of $198.89, suggesting a potential downside of 4.32%. argenex has a consensus target price of $1,157.50, suggesting a potential upside of 13.12%. Given argenex's higher probable upside, analysts clearly believe argenex is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Revolution Medicines had 53 more articles in the media than argenex. MarketBeat recorded 72 mentions for Revolution Medicines and 19 mentions for argenex. Revolution Medicines' average media sentiment score of 0.86 beat argenex's score of 0.40 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	36 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	4 Very Negative mention(s)	Positive
argenex	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has a net margin of 32.19% compared to Revolution Medicines' net margin of 0.00%. argenex's return on equity of 43.59% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
argenex	32.19%	43.59%	36.66%

Summary

Revolution Medicines and argenex tied by winning 8 of the 16 factors compared between the two stocks.

How does Revolution Medicines compare to Moderna?

Moderna (NASDAQ:MRNA) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Revolution Medicines has lower revenue, but higher earnings than Moderna. Revolution Medicines is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	28.34	-$2.82B	-$7.99	N/A
Revolution Medicines	$11.58M	3,847.75	-$1.13B	-$8.82	N/A

Moderna currently has a consensus target price of $80.53, suggesting a potential downside of 41.64%. Revolution Medicines has a consensus target price of $198.89, suggesting a potential downside of 4.32%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Revolution Medicines is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	3 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.17
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

In the previous week, Moderna had 8 more articles in the media than Revolution Medicines. MarketBeat recorded 80 mentions for Moderna and 72 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.86 beat Moderna's score of 0.41 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	35 Very Positive mention(s)	16 Positive mention(s)	7 Neutral mention(s)	10 Negative mention(s)	10 Very Negative mention(s)	Neutral
Revolution Medicines	36 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	4 Very Negative mention(s)	Positive

Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Revolution Medicines	N/A	-88.20%	-57.85%

Summary

Revolution Medicines beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to Natera?

Natera (NASDAQ:NTRA) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

99.9% of Natera shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Natera has higher revenue and earnings than Revolution Medicines. Natera is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.39	-$208.16M	-$1.36	N/A
Revolution Medicines	$11.58M	3,847.75	-$1.13B	-$8.82	N/A

In the previous week, Revolution Medicines had 28 more articles in the media than Natera. MarketBeat recorded 72 mentions for Revolution Medicines and 44 mentions for Natera. Natera's average media sentiment score of 1.21 beat Revolution Medicines' score of 0.86 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	32 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Revolution Medicines	36 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	4 Very Negative mention(s)	Positive

Revolution Medicines has a net margin of 0.00% compared to Natera's net margin of -7.11%. Natera's return on equity of -11.38% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Revolution Medicines	N/A	-88.20%	-57.85%

Natera presently has a consensus price target of $319.38, suggesting a potential downside of 2.11%. Revolution Medicines has a consensus price target of $198.89, suggesting a potential downside of 4.32%. Given Natera's higher probable upside, equities research analysts plainly believe Natera is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Natera has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Summary

Natera beats Revolution Medicines on 9 of the 16 factors compared between the two stocks.

Get Revolution Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVMD vs. The Competition

Export

Metric	Revolution Medicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$44.56B	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-23.57	11.62	273.16	25.45
Price / Sales	3,847.75	1,315.05	614.81	86.98
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	17.10	16.53	12.98	6.14
Net Income	-$1.13B	-$22.80M	$3.48B	$348.86M
7 Day Performance	-0.75%	-0.31%	0.13%	-0.80%
1 Month Performance	8.18%	9.80%	7.08%	4.13%
1 Year Performance	447.48%	55.66%	24.67%	15.17%

Revolution Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVMD Revolution Medicines	2.5137 of 5 stars	$207.88 -6.0%	$198.89 -4.3%	+447.5%	$44.56B	$11.58M	N/A	250	Trending News Analyst Forecast Insider Trade Analyst Revision
VRTX Vertex Pharmaceuticals	3.7861 of 5 stars	$547.59 -0.1%	$563.50 +2.9%	+38.5%	$139.10B	$12.00B	31.87	6,400	Positive News Analyst Downgrade
REGN Regeneron Pharmaceuticals	4.3138 of 5 stars	$828.50 -0.7%	$801.70 -3.2%	+36.8%	$85.87B	$15.53B	20.48	15,410	Trending News
ARGX argenex	4.31 of 5 stars	$1,011.11 -2.8%	$1,118.28 +10.6%	+43.7%	$65.05B	$4.25B	38.83	1,863	Analyst Upgrade
MRNA Moderna	1.4863 of 5 stars	$138.89 -4.3%	$74.31 -46.5%	+472.8%	$57.94B	$1.94B	N/A	4,700	Trending News Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVMD) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revolution Medicines (RVMD) Competitors

RVMD vs. VRTX, REGN, ARGX, MRNA, and NTRA

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Summary

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Summary

How does Revolution Medicines compare to argenex?

Summary

How does Revolution Medicines compare to Moderna?

Summary

How does Revolution Medicines compare to Natera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revolution Medicines (RVMD) Competitors

RVMD vs. VRTX, REGN, ARGX, MRNA, and NTRA

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Do analysts prefer RVMD or VRTX?

Which has more risk & volatility, RVMD or VRTX?

Is RVMD or VRTX more profitable?

Does the media prefer RVMD or VRTX?

Do insiders & institutionals hold more shares of RVMD or VRTX?

Which has stronger valuation and earnings, RVMD or VRTX?

Summary

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Which has more risk & volatility, RVMD or REGN?

Do analysts rate RVMD or REGN?

Do institutionals and insiders hold more shares of RVMD or REGN?

Does the media prefer RVMD or REGN?

Is RVMD or REGN more profitable?

Which has stronger earnings and valuation, RVMD or REGN?

Summary

How does Revolution Medicines compare to argenex?

Which has stronger valuation and earnings, RVMD or ARGX?

Which has more risk and volatility, RVMD or ARGX?

Do analysts rate RVMD or ARGX?

Do insiders and institutionals believe in RVMD or ARGX?

Does the media refer more to RVMD or ARGX?

Is RVMD or ARGX more profitable?

Summary

How does Revolution Medicines compare to Moderna?

Do insiders and institutionals hold more shares of MRNA or RVMD?

Which has stronger valuation & earnings, MRNA or RVMD?

Do analysts rate MRNA or RVMD?

Does the media favor MRNA or RVMD?

Which has more volatility & risk, MRNA or RVMD?

Is MRNA or RVMD more profitable?

Summary

How does Revolution Medicines compare to Natera?

Do institutionals & insiders hold more shares of NTRA or RVMD?

Which has better earnings and valuation, NTRA or RVMD?

Does the media favor NTRA or RVMD?

Is NTRA or RVMD more profitable?

Do analysts rate NTRA or RVMD?

Which has more risk and volatility, NTRA or RVMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools